AlphAIAlphAI — Financial news for AI agents
investing.com$IMCR

Immunocore reports Q3 KIMMTRAK revenue of $102.2 million

Immunocore (NASDAQ:IMCR) reported Q3 2026 KIMMTRAK revenue of $102.2M, down from $103.7M in Q3 2025, with underlying growth of 10%. Net loss was $14.2M, or $0.28 per share. The company announced progress in clinical trials and had $901.3M in cash as of Q3 2026.

Original reporting
investing.com
Published Nov 6, 2026, 2:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 2:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$IMCR
Bearish
high confidence
Mentioned
$IMCR
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IMCRBearishMed
01

Why it matters

The earnings release shows modest revenue growth but a widening loss, suggesting near‑term pressure but a strong cash runway.

02

Market read

The Q3 earnings provide fresh data for traders; the modest revenue decline and loss may trigger short‑term sell pressure, while pipeline milestones could offer upside.

03

What to watch

Cash position of $901M and upcoming Phase 3 overall survival data in Q2 2027 may mitigate short‑term concerns.

Relevance 7/10Novelty 7/10Timing: post-market release

Background

Immunocore Holdings plc is a UK‑based biotech focused on T‑cell receptor therapeutics.

Company-level read

Ticker impact

$IMCRBearishHigh confidence
Context

Immunocore reported Q3 2026 KIMMTRAK revenue of $102.2M, a slight decline YoY and a net loss of $14.2M.

Expected impact

likely downside as market prices in weaker revenue and loss

Evidence & confidence

The company posted lower revenue versus prior year and a sizable net loss, which typically triggers sell pressure.

Market effects

Sector

Biotech sector may see modest caution as a peer reports weaker earnings.

Regional

UK‑based Immunocore's results could slightly affect UK biotech sentiment.

Global

Limited global impact; primarily relevant to investors in biotech and specialty pharma.

Counterpoint

What could challenge this read

Despite the loss, the company's pipeline progress (Phase 3 melanoma trial enrollment) could support a longer‑term upside.

Key entities

  • company
    Immunocore Holdings plc

    Biotech firm developing KIMMTRAK and pipeline candidates.

Read at source← All news

Also covered by

3 outlets

Related articles

$IMCRMed

Immunocore 3Q 2026: Revenue $102.22M, EPS ($0.28) — 10-Q Summary

Immunocore reported a 1.4% YoY revenue decline to $102.22M in Q3 2026, with a widened net loss of $14.22M. U.S. sales fell due to stocking adjustments and fewer sales weeks, partially offset by European and international growth. R&D spending increased, impacting results. KIMMTRAK is approved in 39 countries, and TEBE-AM Phase 3 trial enrollment is complete, with data expected in Q2 2027.

tradingview.com
$IMCRHigh

Immunocore reports third quarter financial results and provides a business update

Immunocore Holdings plc (IMCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date Phase

SEC EDGAR 8-K